| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/12/266:00 AM | -$0.76 | -$0.65GAAP | +14.5% | 0% | — | $0 | — | — | |
| Q2 '26 | 8/12/269:45 PM | -$0.77 | -$0.54 | +29.9% | -8% | — | $0 | — | — | |
| Q1 '26 | 5/20/266:00 AM | -$0.63 | -$0.45GAAP | +28.6% | 0% | — | $0 | — | — | |
| Q4 '25 | 3/2/266:00 AM | -$0.55 | -$0.70GAAP | -27.3% | -119% | — | $0 | — | — | |
| Q3 '25 | 11/10/256:00 AM | -$0.51 | -$0.65GAAP | -27.5% | -132% | — | $0 | — | — | |
| Q2 '25 | 8/11/256:00 AM | -$0.44 | -$0.50GAAP | -13.6% | -92% | — | $0 | — | — | |
| Q1 '25 | 5/13/259:00 PM | -$0.37 | -$0.45GAAP | -21.6% | -36% | — | $0 | — | — |
GAAP = diluted EPS as filed with the SEC. Other EPS figures are adjusted (non-GAAP), the basis analysts estimate.